InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,346.99
(
-0.11%
)
US TECH 100
18,490.00
(
-0.24%
)
Dow Jones
38,798.99
(
-0.22%
)
Brent Oil
79.40
(
0.00%
)
Bitcoin
69,383.91
(
0.07%
)
Post# of 29364
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119787
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Lishur post# 21208

Saturday, 03/07/2020 10:03:57 AM

Saturday, March 07, 2020 10:03:57 AM

Post# of 29364
FGEN is the first company that springs to mind. (Disclosure: No position.) China has an enormous pool of dialysis patients and pre-dialysis patients with chronic kidney disease who are candidates for Roxadustat. AZN markets the drug in China, but FGEN receives royalties on sales.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up